Entera Bio (ENTX) Cash & Equivalents (2017 - 2026)

Entera Bio (ENTX) has reported Cash & Equivalents for 10 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 67.1% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 67.1% YoY) and the FY2025 annual result came in at $7.1 million, down 17.92% from the prior year.
• Cash & Equivalents slipped to $4.1 million in Q1 2026 per ENTX's latest filing, from $7.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ENTX reached as high as $20.1 million in Q1 2022 and fell as low as $4.1 million in Q1 2026.
• A 5-year average of $10.6 million and a median of $9.2 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents surged 36.83% — and 2026, when it plunged 67.1%.
• Year by year, Cash & Equivalents stood at $12.3 million in 2022, then retreated by 10.48% to $11.0 million in 2023, then slipped by 21.41% to $8.7 million in 2024, then decreased by 17.92% to $7.1 million in 2025, then slumped by 41.8% to $4.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.1 million, $7.1 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.